Since its founding more than 60 years ago, Alcon has grown to become a clear leader in eye care by always looking ahead to the future needs of doctors and their patients. With our global footprint and broad product offerings, we are uniquely positioned to benefit from potential growth in demand for new products that will preserve, restore and enhance vision.
For more than 60 years, Alcon has been a trusted leader in ophthalmology by consistently delivering high quality products that meet the needs of patients, doctors and other eye care professionals. We have achieved this leadership position by always looking forward to the future and focusing our entire organization on initiatives that bring the most advanced eye care products to people around the world. The combination of global demographic trends and the significant unmet medical needs that exist in eye care provide a strong base for future growth in the years to come.
Our business strategy is focused on achieving solid financial results on a consistent basis and building a strong foundation for future growth. In 2008, Alcon's sales rose 12.4 percent to $6.29 billion compared to 2007, with important contributions from all of our product categories and geographic regions.
Currency had a favorable 2.9 percent impact on our sales. The remainder of our growth was primarily from unit sales growth, new products and our 2007 acquisition of a majority interest in WaveLight AG. Operating profit rose 17.5 percent to $2.2 billion, even while we made significant investments in our sales force and global infrastructure and continued to fund research and development at high levels. The unprecedented declines and volatility in the financial markets led to a loss of $134 million on our $3.0 billion cash and investment portfolio. Although, these losses were more than offset by a tax agreement of $236 million with the U.S. Internal Revenue Service and a lower effective tax rate arising from tax benefits associated with our establishment of a shared service center in While all of our international markets performed well, emerging markets grew 21.5 percent and now account for 18.3 percent of global sales. These fast-growing markets are characterized by medical needs in eye care that can be substantially met with Alcon's current offerings, and we are highly focused on developing these markets to increase access to our sight-saving technologies. In the United States, challenging economic conditions had a negative effect on market growth in pharmaceuticals, which partially offset solid surgical and consumer sales growth and led to a 5.0 percent increase in U.S. sales to $2.8 billion. of micro-incision cataract surgeries were performed with Alcon equipment, including the most advanced phacoemulsification system on the market today, the Infiniti® vision system. During 2008, we launched the Laureate® world phaco system, which advances the performance of cataract equipment while meeting the specific cost and access needs of emerging markets. We also launched the CONsteLLAtION® vitreoretinal system to replace the Accurus® surgical system, which has been the market leader for almost 10 years. The CONsteLLAtION® significantly increases the safety and efficiency of the complex surgeries that are performed on the retina and in the back of the eye. Finally, we made excellent progress on integrating the acquisition of a majority interest in WaveLight AG and its ALLeGRettO tM refractive laser to expand placements and increase our share of LASIK procedures, albeit in a market that declined sharply due to the economy.
While the foundation of our surgical product line has been built on our equipment platforms, most of our sales come from single-use products, the most important of these being intraocular lenses (IOLs). Alcon maintained its global leadership in IOLs with the continued strong performance of the Acrysof® family of lenses, which topped $1 billion in sales for the first time in our history. We did especially well in advanced technology intraocular lenses, including the Acrysof® RestOR® and Acrysof® toric intraocular lenses, which correct for presbyopia and astigmatism. Together, sales of these lenses increased 46 percent and accounted for almost 20 percent of IOL dollar sales. The market opportunity for these hightechnology lenses is very large. With a market penetration rate of about five percent globally, we expect to see continued strong sales in this category. In December, we received U.S. approval of the Acrysof® RestOR® Aspheric, +3.0 add lens, the latest technology advancement for presbyopia correction.
This new lens significantly improves the range of quality vision for presbyopic cataract patients and will be integral to further expansion of this market and our leadership position in it. • Diluted earnings per share increased 29.3 percent to $6.79.
• The board of directors recommended to increase the annual dividend 50 percent to 3.95 Swiss francs per share.
• Through its global commercial execution capabilities, Alcon achieved broad market share gains in most therapeutic categories.
• Alcon achieved the number two market share position in glaucoma, the largest therapeutic category in ophthalmology.
• The company gained approval of several important new products, including the Acrysof® RestOR® Aspheric, +3.0 add intraocular lens (IOL), Patanase® nasal spray in the United States and Azarga® ophthalmic suspension in the European Union.
• We also are responding to the increasing need to clearly differentiate the benefits of new products versus current therapies by managing our resources and research productivity with even greater discipline.
Without question, the eye care market has some of the most attractive demographics in healthcare. Most eye disease is age-related and there are tremendous unmet medical needs due to lack of access in emerging markets, as well as an opportunity for products that address the underlying causes of eye diseases rather than the symptoms. Furthermore, most eye care drugs and devices are relatively low cost and deliver significant improvements in quality of life, effectively delivering an excellent cost-benefit for individuals and societies.
To address the future demand for our products, we began the design, engineering and construction on three major capital projects in 2008. We started construction in 2009 in Singapore of our first pharmaceutical plant in Asia. This facility will service the rapidly growing needs of the emerging countries in this region. We also commenced two projects to expand our IOL manufacturing facilities in Huntington, West Virginia, and Cork, Ireland. These expansions reflect not only the need to meet especially the research and development of new products and demand creation for existing products. I firmly believe that by doing this, and with appropriate management of our overall cost structure, we will emerge from this difficult period even stronger than we are today.
In conclusion, I would like to thank our 15,000 employees in more than 75 countries who dedicate themselves to making Alcon the first choice for eye care products and the trusted partner of eye care professionals around the world. It is their hard work and dedication that has made Alcon the leader in eye care today, and that will support our growth in the future.
Together with eye care professionals around the world, we will bring more and better solutions for eye disease to more people. 
Cary Rayment

Global Execution Capability
A critical component of our success in serving the needs of the eye care community around the world is our ability to develop, manufacture, deliver, service and market high-quality products on a global basis.
Global sales Reach throughout eye Care
The Alcon global sales force is the largest and one of the best-trained ophthalmic sales forces in the industry today. We have more than organization and our strong product portfolio has given Alcon a significant advantage over our competition to grow our market share around the world.
Manufacturing and Distribution Network
Given the nature of our products, quality and precision are at the forefront of our manufacturing operations. Alcon is known as a trusted partner in ophthalmology, not only because of the efficacy and safety of our products, but also because of our ability to manufacture high-quality products that meet the needs of doctors, patients and consumers.
We manufacture our products in 13 locations on three continents. Each plant is specialized to meet the highest standards of quality and efficiency to ensure that the safety of our products is never compromised. We then support the local markets by delivering and servicing our products through our own distribution network, which spans more than 75 countries. This network delivers the highest level of customer service in all markets while effectively managing our costs. It also allows us to interact directly with our customers, rather than through distributors that may not be totally focused on Alcon's products and customers.
Adapting to Changing environments
As we continue to see demand for our products increase in emerging markets, primarily in Alcon's success is supported by the breadth and quality of our products, solid commercial execution, world-class employees and a commitment to innovation. Building on this solid foundation, our future will continue to be fueled by an expanding patient base as people age, the introduction of existing products into new markets and the discovery and development of products in new therapeutic areas.
Demographic trends
The United Nations estimated that the global population over 65 years of age will more than double by 2030. Although the consumption of eye care products spans all demographic categories, the World Health Organization estimates about 75 percent of eye disease is associated with aging.
As medical technology expands and the global standard of living continues to rise, people will not only live longer, but will also require greater access to high-quality medical care. We believe that these demographic trends should drive increasing demand for eye care products for many years to come.
Market Development
Alcon's products are currently distributed across the globe, but there remains a significant opportunity to introduce key products into new markets, as well as to further develop underserved countries. Global While the majority of our sales originate in developed countries, we are committed to extending and enhancing our infrastructure in emerging markets to fulfill the need for eye care products and services in these underserved areas.
Significant opportunity exists to improve the quality of eye care with advancements in cataract surgery, through the expansion of small-incision phacoemulsification and high-quality, foldable intraocular lenses. We expect the Laureate® world phaco system and the Acrysof® intraocular lens will be the cornerstone of this growth.
Unmet Medical Needs
The discovery and development of products and therapies to treat unmet medical needs or those with limited current therapies, such as age-related macular degeneration and dry eye, will be the foundation for future growth in the eye care field.
Another example is glaucoma, where current medications only treat symptoms of the disease but not its underlying causes. Significant opportunities also exist to customize visual outcomes for cataract patients and provide them with the full visual capabilities they had when they were younger.
Our continued investment in and commitment
to ophthalmic research is the basis for the future discovery of new technologies that will preserve, restore and enhance vision. We believe that our longstanding track record of innovation and product development combined with our commercial capabilities will allow us to bring new products to market to address these unmet medical needs and fuel our growth in the future.
Commitment to Innovation
Alcon's mission is to develop products that improve the quality of life by helping people see better.
Although we currently offer an industry-leading breadth of innovative products across the globe, there are underserved ophthalmic conditions and disease causalities that remain untreated by available science and technology. Our focus on these unmet medical needs, and our commitment to near-and long-term pipeline development, ensure that Alcon will significantly influence the next generation of ophthalmic treatment. Alcon's position within the eye care industry is a direct result of the dedicated efforts of our world-class researchers and our proven capability to discover and develop new products. We are committed to bringing new and incremental therapies to the market to address unmet medical needs and improve ocular health because we know that doctors and their patients are waiting.
Broad and Diverse Product Portfolio
Alcon offers the broadest line of eye care products available to the eye care professional.
The breadth of our product portfolio and our unwavering dedication to continually bring new products to market that advance the standard of care and enable people to see better has made Alcon the industry's recognized global leader.
Market Leadership
Alcon has many leading market share positions across its three major product lines: Pharmaceutical, Surgical and Consumer. These positions are a result of our commercial execution capability through which we communicate the benefits of our product portfolio.
Pharmaceutical
In the largest and most important ocular Systane® family of products is leading the growth of over-the-counter artificial tears, while the ICAPS® brand of ocular vitamins is the number two brand in this product category.
Product Line Growth and Expansion
Alcon is continuing to broaden its comprehensive line of market-leading products and advance its market leadership position of key brands.
New product approvals and significant growth in many therapeutic categories extended across all three product lines.
Technology Drives Surgical Growth
The year was marked with significant growth and product line expansion for our 
Glaucoma Fuels Pharmaceutical Sales
Alcon experienced significant sales growth with its line of intraocular pressure lowering ophthalmic solutions for treatment of patients with glaucoma. 
Global Brands Lead Consumer Products
Alcon's consumer vision care franchise continues to see growth due to successful globalization and market retention strategies with the newest product in the OPtI-FRee® line, OPtI-FRee® ReplenisH®.
We also continued to innovate in the dry eye category with the U.S. launch of systane® Ultra, which provides the same protection and comfort of systane® in a droppable gel that reduces blurring on instillation. The systane® brand of products is now the number one doctor recommended over- • Over the past three years, Alcon has contributed $136 million in financial and product support to charitable organizations.
• Alcon donates pharmaceutical products and surgical equipment to countries in need, supporting more than 1,200 medical missions a year.
• The Alcon Foundation provides grants to U.S.-based philanthropies, however, its impact is worldwide. Alcon supports ORBIS and Mercy Ships, which both provide ophthalmic benefits to less fortunate people around the world. Phone: 1-800-400-8599
Copies are also available for physical inspection at the company's headquarters at the address above. 
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